Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The company’s shares closed last Friday at p1,466. ...

NEW YORK CITY, NY / ACCESS Newswire / March 11, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

The market was pleased with the recent earnings report from GSK plc (LON:GSK), despite the profit numbers being soft. However, we think the company is showing some signs that things are more ...

Tony Wood, Chief Scientific Officer, GSK, said: "We are excited about the ... a life stage when they are at an increased risk." Judy Klein, President and Founder of Unity Consortium, a non-profit ...

LONDON, - British drugmaker GSK will no longer set diversity targets, it said on Thursday, as it became the latest company to scale back or abandon such goals in response to the U.S. president's ...

Smith reminds investors that class action lawsuits ... and/or misleading statements and/or failed to disclose that: (1) GSK was fully aware of the source of NDMA and had been for nearly 40 years ...

Feb 15 (Reuters) - The U.S. Food and Drug Administration approved British drugmaker GSK's (GSK.L), opens new tab combination vaccine to protect against meningococcal infection for use in people ...

It has been about a month since the last earnings report for GSK (GSK). Shares have added about 8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. UK drugmaker GSK is struggling to convince the market that it can deliver on its plans to refill its ...

Now, GSK is ready to play catch-up after nabbing its own FDA approval. The FDA approved the British drugmaker's Penmenvy vaccine to protect people ages 10 to 25 against meningococcal serogroups A ...

GSK's revenue and EPS exceeded my expectations and those of analysts, thanks to the strong performance of its oncology and HIV franchises. So, Ojjaara/Omjjara sales amounted to $150 million in the ...

GlaxoSmithKline share price jumped more than 17% on Tuesday and extended its surge for the third consecutive session. GlaxoSmithKline shares spiked as much as 17.69% to ₹2,744.95 apiece on the ...